Published in Brain on June 01, 2005
Advancing translational research with the Semantic Web. BMC Bioinformatics (2007) 4.38
The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.65
Dystonia in Parkinson's disease. J Neurol (2006) 1.30
The hypothesis of apraxia of speech in children with autism spectrum disorder. J Autism Dev Disord (2011) 1.08
Visual spatial cognition in neurodegenerative disease. Neurocase (2010) 1.03
Update on apraxia. Curr Neurol Neurosci Rep (2008) 0.97
Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. Parkinsons Dis (2011) 0.91
Assessment of dentally related functional competency for older adults with cognitive impairment--a survey for special-care dental professionals. Spec Care Dentist (2012) 0.87
Cortico-cortical networks in patients with ideomotor apraxia as revealed by EEG coherence analysis. Neurosci Lett (2008) 0.86
Association of ideomotor apraxia with frontal gray matter volume loss in corticobasal syndrome. Arch Neurol (2009) 0.85
Gait and dementia: moving beyond the notion of gait apraxia. J Neural Transm (Vienna) (2007) 0.85
Apraxia of tool use is not a matter of affordances. Front Hum Neurosci (2013) 0.85
Clinical Reasoning: a woman with rapidly progressive apraxia. Neurology (2013) 0.84
Toward a narrower, more pragmatic view of developmental dyspraxia. J Child Neurol (2010) 0.82
Short and valid assessment of apraxia in Parkinson's disease. Parkinsonism Relat Disord (2011) 0.81
Cognitive profiles in Parkinson's disease and their relation to dementia: a data-driven approach. Int J Alzheimers Dis (2012) 0.79
Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up. Phys Ther (2013) 0.78
Cognitive impairment, oral self-care function and dental caries severity in community-dwelling older adults. Gerodontology (2013) 0.78
The c.429_452 duplication of the ARX gene: a unique developmental-model of limb kinetic apraxia. Orphanet J Rare Dis (2014) 0.77
Progression of logopenic variant primary progressive aphasia to apraxia and semantic memory deficits. BMC Neurol (2013) 0.77
From Intention to Action: Hierarchical Sensorimotor Transformation in the Posterior Parietal Cortex(12). eNeuro (2014) 0.76
Assessment of Dentally Related Function in Individuals with Cognitive Impairment: The Dental Activities Test. J Am Geriatr Soc (2017) 0.75
Right putamen hemorrhage manifesting as apraxia of eyelid opening. Neuropsychiatr Dis Treat (2013) 0.75
Apraxia and motor dysfunction in corticobasal syndrome. PLoS One (2014) 0.75
Forward Prediction in the Posterior Parietal Cortex and Dynamic Brain-Machine Interface. Front Integr Neurosci (2016) 0.75
The Representation of Objects in Apraxia: From Action Execution to Error Awareness. Front Hum Neurosci (2016) 0.75
Disentangling the neural correlates of corticobasal syndrome and corticobasal degeneration with systematic and quantitative ALE meta-analyses. NPJ Parkinsons Dis (2017) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47
Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46
Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46
Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol (2006) 1.42
Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol (2002) 1.40
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Definition and classification of hyperkinetic movements in childhood. Mov Disord (2010) 1.38
Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol (2002) 1.36
Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol (2006) 1.34
Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32
Gait abnormalities in psychogenic movement disorders. Mov Disord (2007) 1.32
Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol (2006) 1.31
The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet (2004) 1.29
Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28
The nonmotor symptoms of Parkinson's disease--an overview. Mov Disord (2010) 1.25
Movement disorders on YouTube--caveat spectator. N Engl J Med (2011) 1.25
The many faces of corticobasal degeneration. Parkinsonism Relat Disord (2007) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord (2003) 1.19
Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19
Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol (2010) 1.16
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol (2004) 1.14
Pallidal neuronal activity: implications for models of dystonia. Ann Neurol (2003) 1.14
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology (2013) 1.14
Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study. Hum Brain Mapp (2009) 1.13
Dystonia in complex regional pain syndrome type I. Ann Neurol (2010) 1.13
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord (2006) 1.13
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology (2003) 1.12
ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord (2009) 1.12